Evidence map›Paper›PMID 22615584›Full record

ArticlePLoS genetics2012

Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/- mice.

Quan Yuan, Tadatoshi Sato, Michael Densmore, Hiroaki Saito, Christiane Schüler, Reinhold G Erben, Beate Lanske

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice.Journal of molecular medicine (Berlin, Germany) · 2016
    Article
  19. DNA NBone research · 2016
    Article
  20. Fibroblast growth factor 23 and bone mineralisation.International journal of oral science · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Quan YuanDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, Massachusetts, United States of America.
Tadatoshi Sato
Michael Densmore
Hiroaki Saito
Christiane Schüler
Reinhold G Erben
Beate Lanske
Harvard University · USUniversity of Veterinary Medicine Vienna · AT

Funding

Pathophysiologic Regulation of Fgf-23 in Phosphate Homeostasis: Role of Vitamin DR01DK073944 · NIDDK · HARVARD MEDICAL SCHOOL · PI MANNSTADT, BEATE · 2007 to 2010
$1.7M
NIDDK NIH HHS R01 DK073944PHS HHS NIH/NIDDK R01-073944
6 · The paper itself

Abstract

Maintenance of normal mineral ion homeostasis is crucial for many biological activities, including proper mineralization of the skeleton. Parathyroid hormone (PTH), Klotho, and FGF23 have been shown to act as key regulators of serum calcium and phosphate homeostasis through a complex feedback mechanism. The phenotypes of Fgf23(-/-) and Klotho(-/-) (Kl(-/-)) mice are very similar and include hypercalcemia, hyperphosphatemia, hypervitaminosis D, suppressed PTH levels, and severe osteomalacia/osteoidosis. We recently reported that complete ablation of PTH from Fgf23(-/-) mice ameliorated the phenotype in Fgf23(-/-)/PTH(-/-) mice by suppressing serum vitamin D and calcium levels. The severe osteomalacia in Fgf23(-/-) mice, however, persisted, suggesting that a different mechanism is responsible for this mineralization defect. In the current study, we demonstrate that deletion of PTH from Kl(-/-) (Kl(-/-)/PTH(-/-) or DKO) mice corrects the abnormal skeletal phenotype. Bone turnover markers are restored to wild-type levels; and, more importantly, the skeletal mineralization defect is completely rescued in Kl(-/-)/PTH(-/-) mice. Interestingly, the correction of the osteomalacia is accompanied by a reduction in the high levels of osteopontin (Opn) in bone and serum. Such a reduction in Opn levels could not be observed in Fgf23(-/-)/PTH(-/-) mice, and these mice showed sustained osteomalacia. This significant in vivo finding is corroborated by in vitro studies using calvarial osteoblast cultures that show normalized Opn expression and rescued mineralization in Kl(-/-)/PTH(-/-) mice. Moreover, continuous PTH infusion of Kl(-/-) mice significantly increased Opn levels and osteoid volume, and decreased trabecular bone volume. In summary, our results demonstrate for the first time that PTH directly impacts the mineralization disorders and skeletal deformities of Kl(-/-), but not of Fgf23(-/-) mice, possibly by regulating Opn expression. These are significant new perceptions into the role of PTH in skeletal and disease processes and suggest FGF23-independent interactions of PTH with Klotho.

Indexed as

Calcification, PhysiologicFibroblast Growth FactorsGlucuronidaseOsteopontinParathyroid HormoneAnimalsBone and BonesCalciumFibroblast Growth Factor-23Gene Expression RegulationKlotho ProteinsMiceMice, TransgenicOsteoblastsOsteomalaciaPhosphatesCalciumFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsGlucuronidaseKlotho ProteinsOsteopontinParathyroid HormonePhosphatesVitamin D

Identifiers

PMID22615584
PMCPMC3355080
OpenAlexW1986741321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.